This package is for Laboratory Professionals; Clinicians should see the individual update courses for CME credits. 2018 IO Update 1 and 2018 IO Update 2
ASCP Scientific Updates are a quarterly series of 30-minute on-demand webcasts containing up-to-the-minute information on various therapeutic agents, disease states, and thresholds that impact immuno-oncology diagnostics in solid tumors and hematologic malignancies.
ASCP Scientific Updates: Molecular Marker Testing Recommendations for Lung Cancer Treatment
This webcast addresses the latest molecular marker testing recommendations for lung cancer treatment. The guidelines for non–small cell lung cancer (NSCLC) are changing quickly, with new updates and modifications of recommendations released in early 2018. To treat advanced stage lung cancer patients rapidly, it's important to stay up-to-date on the appropriate tests.
This course is designed to educate pathologists and laboratory personnel on the sensitive assays and new technologies involved in lung cancer testing. You will learn a general overall view of the current state of molecular testing in lung cancer. Additionally, you will learn about the exciting and evolving role of next generation sequencing (NGS) and circulating cfDNA (liquid biopsy) in lung cancer testing, as well as the limitations in small biopsies. The significant role of immunohistochemistry (IHC) for single-gene assessments, ALK, and ROS1 testing are also discussed. The course will help you understand the guidelines that will lead to more uniform testing in a clinically reliable way across the laboratory profession.
Learning Objectives:
As a result of participating in this course, learners will be able to:
- Describe the changes in lung cancer testing and treatment happening at a rapid pace
- Discuss current lung cancer guidelines and recommendations, including the role of immunotherapy and PD-L1 testing
- Describe the roles of ALK, EGFR, and ROS1 testing in treatment decisions
- Discuss the roles and limitations of next generation sequencing (NGS) and liquid biopsy (cf-DNA) testing in lung cancers
Faculty:
Mamatha Chivukula, MD, FASCP
Director of Immunohistochemistry Lab and Breast Pathology Services
Mills-Peninsula Hospital, Sutter Health Affiliate
Immuno-Oncology Scientific Updates: An Introduction to CAR T-Cell Therapy
This webcast will provide participants with a basic understanding of CAR T cell biology and design. You’ll learn about activation of B cells and T cells, as well as current CAR T cell targets. This webcast will also provide an overview of how CAR T cells are manufactured and describe future directions in the field.
Learning Objectives:
As a result of participating in this course, learners will be able to:
• Describe the basics on CAR T-cell biology and design
• Discuss currently available CAR T-cell therapy targets
• Explain highlights of the CAR T-cell manufacturing process
• Discuss the future of CAR T cell therapy
Faculty:
Andrew D. Fesnak, MD
Assistant Professor of Clinical Pathology and Laboratory Medicine
University of Pennsylvania Perelman School of Medicine
Credit Designation Statement
The ASCP designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
ASCP designates these live activities for a maximum of 1.0 CMLE credit. These activities meet CMP and state re-licensure requirements for laboratory personnel.
For questions regarding CMLE credit, please contact ASCP Customer Service at 1-800-267-2727, during normal business hours: Monday through Friday, 8 a.m. to 6 p.m. Eastern Time
Method of Participation
To complete the activity and receive credit, the participant must complete the online course. CME certificates will be provided on-line.
Funded by an independent educational grant from AstraZeneca.